PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Long non-coding RNA tumor suppressor candidate 7 advances chemotherapy sensitivity of endometrial carcinoma through targeted silencing of miR-23b.

Abstract Endometrial carcinoma is the most common malignant tumor of the female genital tract worldwide. TUSC7 (tumor suppressor candidate 7) is an antisense long non-coding RNA and is downregulated and acts as a potential tumor suppressor in several malignant tumors. In this study, the low expression of TUSC7 was confirmed in endometrial carcinoma tissues and was associated with high pathological stages of endometrial carcinoma, which revealed that TUSC7 might be involved in tumorigenesis and progression of endometrial carcinoma. Moreover, the expression of TUSC7 in endometrial carcinoma tissues and cell lines resistant to CDDP and Taxol was lower than that in sensitive endometrial carcinoma tissues and cell lines, which indicated that the TUSC7 expression level was positively correlated with the response of endometrial carcinoma patients to chemotherapy with CDDP and Taxol. TUSC7 upregulation inhibited proliferation, blocked cells at G1 phase, and advanced apoptosis and chemotherapy sensitivity to CDDP and Taxol in HEC1A/CR cell line. Furthermore, miR-23b was upregulated in endometrial carcinoma and negatively correlated with the expression of TUSC7. RNA pull-down assay indicated that TUSC7 could specifically silence the expression of miR-23b in HEC1A/CR cell line; miR-23b was a target gene of TUSC7. MiR-23b upregulation mostly reversed the TUSC7-induced regulatory effects on HEC1A/CR cell line. In summary, long non-coding RNA TUSC7 was underexpressed in endometrial carcinoma, especially in endometrial carcinoma chemotherapy-resistant tissues and cell lines and acted as a potential tumor suppressor gene to inhibit cell growth as well as advance the chemotherapy sensitivity through targeted silencing of miR-23b, which might provide a new therapeutic target to endometrial carcinoma.
PMID
Related Publications

Long non-coding RNA tumor suppressor candidate 7 functions as a tumor suppressor and inhibits proliferation in osteosarcoma.

Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma.

Reciprocal repression between TUSC7 and miR-23b in gastric cancer.

The Novel Long Noncoding RNA TUSC7 Inhibits Proliferation by Sponging MiR-211 in Colorectal Cancer.

Long Non-coding RNA TUSC7, a Target of miR-23b, Plays Tumor-Suppressing Roles in Human Gliomas.

Authors

Mayor MeshTerms
Keywords

Endometrial carcinoma

chemotherapy

long non-coding RNA

miciroRNA-23b

tumor suppressor candidate 7

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28653877
OWN - NLM
STAT- MEDLINE
DA  - 20170627
DCOM- 20170711
LR  - 20170713
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Long non-coding RNA tumor suppressor candidate 7 advances chemotherapy
      sensitivity of endometrial carcinoma through targeted silencing of miR-23b.
PG  - 1010428317707883
LID - 10.1177/1010428317707883 [doi]
AB  - Endometrial carcinoma is the most common malignant tumor of the female genital
      tract worldwide. TUSC7 (tumor suppressor candidate 7) is an antisense long
      non-coding RNA and is downregulated and acts as a potential tumor suppressor in
      several malignant tumors. In this study, the low expression of TUSC7 was
      confirmed in endometrial carcinoma tissues and was associated with high
      pathological stages of endometrial carcinoma, which revealed that TUSC7 might be 
      involved in tumorigenesis and progression of endometrial carcinoma. Moreover, the
      expression of TUSC7 in endometrial carcinoma tissues and cell lines resistant to 
      CDDP and Taxol was lower than that in sensitive endometrial carcinoma tissues and
      cell lines, which indicated that the TUSC7 expression level was positively
      correlated with the response of endometrial carcinoma patients to chemotherapy
      with CDDP and Taxol. TUSC7 upregulation inhibited proliferation, blocked cells at
      G1 phase, and advanced apoptosis and chemotherapy sensitivity to CDDP and Taxol
      in HEC1A/CR cell line. Furthermore, miR-23b was upregulated in endometrial
      carcinoma and negatively correlated with the expression of TUSC7. RNA pull-down
      assay indicated that TUSC7 could specifically silence the expression of miR-23b
      in HEC1A/CR cell line; miR-23b was a target gene of TUSC7. MiR-23b upregulation
      mostly reversed the TUSC7-induced regulatory effects on HEC1A/CR cell line. In
      summary, long non-coding RNA TUSC7 was underexpressed in endometrial carcinoma,
      especially in endometrial carcinoma chemotherapy-resistant tissues and cell lines
      and acted as a potential tumor suppressor gene to inhibit cell growth as well as 
      advance the chemotherapy sensitivity through targeted silencing of miR-23b, which
      might provide a new therapeutic target to endometrial carcinoma.
FAU - Shang, Chao
AU  - Shang C
AD  - 1 Department of Neurobiology, China Medical University, Shenyang, P.R. China.
FAU - Lang, Bin
AU  - Lang B
AD  - 2 School of Health Sciences, Macao Polytechnic Institute, Macao, P.R. China.
FAU - Ao, Cheng Ngok
AU  - Ao CN
AD  - 2 School of Health Sciences, Macao Polytechnic Institute, Macao, P.R. China.
FAU - Meng, Lirong
AU  - Meng L
AD  - 2 School of Health Sciences, Macao Polytechnic Institute, Macao, P.R. China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (MIRN23 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (long non-coding RNA TUSC7, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Apoptosis/genetics
MH  - Carcinogenesis/genetics
MH  - Cell Proliferation/genetics
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Endometrial Neoplasms/drug therapy/*genetics/pathology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, Tumor Suppressor
MH  - Humans
MH  - MicroRNAs/antagonists & inhibitors/*genetics
MH  - Middle Aged
MH  - RNA, Long Noncoding/*genetics
OTO - NOTNLM
OT  - Endometrial carcinoma
OT  - chemotherapy
OT  - long non-coding RNA
OT  - miciroRNA-23b
OT  - tumor suppressor candidate 7
EDAT- 2017/06/28 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/28 06:00
AID - 10.1177/1010428317707883 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317707883. doi: 10.1177/1010428317707883.